Meeting
2021 ASCO Annual Meeting
A phase II/III study of perioperative nivolumab and ipilimumab in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of a safety run-in—A trial of the ECOG-ACRIN Cancer Research Group (EA2174).
Authors
Jennifer Rachel Eads
University of Pennsylvania Abramson Cancer Center, Philadelphia, PA
Jennifer Rachel Eads , Michelle Weitz , Paul J. Catalano , Michael K. Gibson , Lakshmi Rajdev , Onkar Khullar , Steven H. Lin , Constantine Gatsonis , Ignacio Ivan Wistuba , Aravind Sanjeevaiah , Al Bowen Benson III, Nathan Bahary , Kristen Renee Spencer , Nabil F. Saba , Stanley R. Hamilton , Charles A. Staley , Bapsi Chakravarthy , George A. Fisher Jr., Terence Z. Wong , Peter J. O'Dwyer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT03604991
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 4064)
DOI
10.1200/JCO.2021.39.15_suppl.4064
Abstract #
4064
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A phase II/III study of perioperative nivolumab and ipilimumab in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: A trial of the ECOG-ACRIN Cancer Research Group (EA2174).
First Author: Jennifer Rachel Eads
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases.
First Author: Jianbo Wang
First Author: Sylvie Lorenzen
Poster
2014 ASCO Annual Meeting
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results.
First Author: Scott Joseph Antonia